{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:40:53Z","timestamp":1791499253821,"version":"4.3.4"},"reference-count":25,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Virus-specific T-cells (VSTs) from third-party donors mediate short- and long-term antiviral effects in allogeneic hematopoietic stem cell transplant (HSCT) recipients with relapsed or refractory viral infections. We investigated early administration of third-party VSTs, together with antiviral therapy in patients requiring treatment for first cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection. Thirty HSCT patients were treated with 1 to 4 VST infusions (2 \u00d7 107 cells\/m2; CMV n=27, EBV n=3) at a median of 4 days after initiation of antiviral treatment. The overall viral response rate was 100%, with a complete response (CR) rate of 94%. Of the 28 patients who achieved a CR, 23 remained virus PCR negative (n=9) or below quantitation limit (n=14) for the duration of follow-up. Four patients had brief episodes of quantifiable reactivation not requiring additional therapy, and one required a second infusion after initial CR, remaining PCR negative thereafter. All 3 patients treated for EBV post-transplant lymphoproliferative disorder achieved sustained CR. Rates of aGVHD and cGVHD after infusion were 13% and 23%, respectively. There were no serious infusion-related adverse events. VST infusion was associated with rapid recovery of CD8+CD45RA\u2212CD62L\u2212 and a slower recovery of CD4+CD45RA\u2212CD62L\u2212 effector memory T-cells; CMV-specific T-cells comprised up to 13% of CD8+ cells. At 1 year post-transplant, non-relapse mortality was 10%, cumulative incidence of relapse was 7%, overall survival was 88% and 25 of 27 patients had ECOG status of 0 or 1. Early administration of third-party VSTs in conjunction with antiviral treatment appears safe and leads to excellent viral control and clinical outcomes. Registered on Australian New Zealand Clinical Trials Registry as #ACTRN12618000343202.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007103","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T11:35:51Z","timestamp":1657625751000},"page":"4949-4966","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":54,"title":["Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1049-7239","authenticated-orcid":false,"given":"Wei","family":"Jiang","sequence":"first","affiliation":[{"name":"1Sydney Medical School, Faculty of Medicine and Health, and"},{"name":"2Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leighton E.","family":"Clancy","sequence":"additional","affiliation":[{"name":"2Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selmir","family":"Avdic","sequence":"additional","affiliation":[{"name":"1Sydney Medical School, Faculty of Medicine and Health, and"},{"name":"2Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Sutrave","sequence":"additional","affiliation":[{"name":"2Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia;"},{"name":"3Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Westmead, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Street","sequence":"additional","affiliation":[{"name":"2Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Simms","sequence":"additional","affiliation":[{"name":"2Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2047-6543","authenticated-orcid":false,"given":"Helen M.","family":"McGuire","sequence":"additional","affiliation":[{"name":"4Ramaciotti Facility for Human Systems Biology, and"},{"name":"5Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia;"},{"name":"6Infection, Immunity, and Inflammation Theme, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5253-4747","authenticated-orcid":false,"given":"Ellis","family":"Patrick","sequence":"additional","affiliation":[{"name":"2Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia;"},{"name":"7School of Mathematics and Statistics, Faculty of Science, The University of Sydney, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9949-0342","authenticated-orcid":false,"given":"Adam S.","family":"Chan","sequence":"additional","affiliation":[{"name":"7School of Mathematics and Statistics, Faculty of Science, The University of Sydney, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4838-9022","authenticated-orcid":false,"given":"Georgia","family":"McCaughan","sequence":"additional","affiliation":[{"name":"3Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Westmead, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadav","family":"Myers","sequence":"additional","affiliation":[{"name":"2Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth P.","family":"Micklethwaite","sequence":"additional","affiliation":[{"name":"1Sydney Medical School, Faculty of Medicine and Health, and"},{"name":"2Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia;"},{"name":"8Blood Transplant and Cell Therapies Laboratory, Institute for Clinical Pathology and Medical Research, NSW Health Pathology, Westmead, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Antonenas","sequence":"additional","affiliation":[{"name":"8Blood Transplant and Cell Therapies Laboratory, Institute for Clinical Pathology and Medical Research, NSW Health Pathology, Westmead, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian G.","family":"Selim","sequence":"additional","affiliation":[{"name":"9Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ritchie","sequence":"additional","affiliation":[{"name":"9Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia;"},{"name":"10Department of Medicine, University of Melbourne, Victoria, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2759-8279","authenticated-orcid":false,"given":"Caroline M.","family":"Bateman","sequence":"additional","affiliation":[{"name":"1Sydney Medical School, Faculty of Medicine and Health, and"},{"name":"2Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia;"},{"name":"11Oncology Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0101-4482","authenticated-orcid":false,"given":"Peter J.","family":"Shaw","sequence":"additional","affiliation":[{"name":"1Sydney Medical School, Faculty of Medicine and Health, and"},{"name":"12Bone Marrow Transplant and Cell Therapies Unit, Children\u2019s Hospital at Westmead, Westmead, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7849-7139","authenticated-orcid":false,"given":"Emily","family":"Blyth","sequence":"additional","affiliation":[{"name":"1Sydney Medical School, Faculty of Medicine and Health, and"},{"name":"2Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia;"},{"name":"3Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Westmead, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"1Sydney Medical School, Faculty of Medicine and Health, and"},{"name":"2Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia;"},{"name":"3Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Westmead, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"issue":"16","key":"2022082615225476000_B1","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood."},{"issue":"3","key":"2022082615225476000_B2","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol."},{"issue":"2","key":"2022082615225476000_B3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/bmt.2013.96","article-title":"EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT","volume":"49","author":"Rasche","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"2022082615225476000_B4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bbmt.2004.11.010","article-title":"Immune reconstitution: the major barrier to successful stem cell transplantation","volume":"11","author":"Antin","year":"2005","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2022082615225476000_B5","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.V100.6.2235","article-title":"Direct evidence for new T-cell generation by patients after either T-cell\u2013depleted or unmodified allogeneic hematopoietic stem cell transplantations","volume":"100","author":"Lewin","year":"2002","journal-title":"Blood."},{"issue":"2","key":"2022082615225476000_B6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.V93.2.467","article-title":"Comparison of immune reconstitution after unrelated and related T-cell\u2013depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions","volume":"93","author":"Small","year":"1999","journal-title":"Blood."},{"issue":"12","key":"2022082615225476000_B7","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1086\/648422","article-title":"Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation","volume":"49","author":"Peggs","year":"2009","journal-title":"Clin Infect Dis."},{"issue":"5","key":"2022082615225476000_B8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.bbmt.2013.01.021","article-title":"Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex\u00a0vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution","volume":"19","author":"Clancy","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2022082615225476000_B9","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood."},{"issue":"23","key":"2022082615225476000_B10","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","article-title":"Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes","volume":"116","author":"Barker","year":"2010","journal-title":"Blood."},{"issue":"26","key":"2022082615225476000_B11","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood."},{"issue":"24","key":"2022082615225476000_B12","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv."},{"issue":"12","key":"2022082615225476000_B13","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.bbmt.2018.08.024","article-title":"Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program","volume":"24","author":"Withers","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2022082615225476000_B14","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"2022082615225476000_B15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"2022082615225476000_B16","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/cid\/cix804","article-title":"Kinetics of double-stranded DNA viremiaafter allogeneic hematopoietic cell transplantation","volume":"66","author":"Hill","year":"2018","journal-title":"Clin Infect Dis."},{"issue":"8","key":"2022082615225476000_B17","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis."},{"issue":"7","key":"2022082615225476000_B18","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","volume":"28","author":"Younes","year":"2017","journal-title":"Ann Oncol."},{"issue":"18","key":"2022082615225476000_B19","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood."},{"issue":"5","key":"2022082615225476000_B20","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.bbmt.2017.12.802","article-title":"Ultra-sensitive droplet digital PCR for the assessment of microchimerism in cellular therapies","volume":"24","author":"Kliman","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"2022082615225476000_B21","volume-title":"A Language and Environment for Statistical Computing.","author":"R Core Team","year":"2020"},{"issue":"1","key":"2022082615225476000_B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw."},{"issue":"10","key":"2022082615225476000_B23","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1038\/leu.2017.16","article-title":"Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT","volume":"31","author":"Neuenhahn","year":"2017","journal-title":"Leukemia."},{"issue":"31","key":"2022082615225476000_B24","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human Herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol."},{"issue":"7","key":"2022082615225476000_B25","doi-asserted-by":"crossref","first-page":"e1149","DOI":"10.1002\/cti2.1149","article-title":"Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMV-specific T cells","volume":"9","author":"McGuire","year":"2020","journal-title":"Clin Transl Immunology."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/17\/4949\/1916916\/advancesadv2022007103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/17\/4949\/1916916\/advancesadv2022007103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T11:40:57Z","timestamp":1661514057000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/17\/4949\/485870\/Third-party-CMV-and-EBV-specific-T-cells-for-first"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":25,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022,9,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007103","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]}}}